United Therapeutics CORP Form 4 insider transactions

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales of common stock under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on August 1st and 2nd, 2024, under a pre-arranged 10b5-1 trading plan.

Director Raymond Dwek exercised stock options and sold shares of United Therapeutics Corp (UTHR) on August 2, 2024.

Martine Rothblatt, Chairperson & CEO of United Therapeutics, executed a series of stock option exercises and sales on July 31, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on July 29 and 30, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on July 25 and 26, 2024, under a pre-arranged 10b5-1 trading plan.

Director Judy D. Olian reports the acquisition of 1,190 restricted stock units in United Therapeutics Corporation.

Director Richard Giltner reports acquisition of 1,190 restricted stock units in United Therapeutics Corp.

Director Christopher Causey received 1,190 restricted stock units of United Therapeutics Corporation on July 25, 2024, which vest on the one-year anniversary of the grant date.

Director Tommy G. Thompson acquired 2,890 stock options in United Therapeutics Corp on July 25, 2024, as part of an annual non-employee director award.

Director Louis W. Sullivan reports acquisition of stock options and restricted stock units in United Therapeutics Corp.

Director Linda Maxwell reports the acquisition of 2,890 stock options in United Therapeutics Corp.

Director Christopher Patusky reports acquisition of stock options and restricted stock units in United Therapeutics Corp.

Director Nilda Mesa received stock options and restricted stock units as part of an annual non-employee director award from United Therapeutics Corporation.

Director Jan Malcolm reports the acquisition of stock options and restricted stock units in United Therapeutics Corporation.

Director Ray Kurzweil reports the acquisition of stock options and restricted stock units in United Therapeutics Corporation.

Raymond Dwek, a director at United Therapeutics, acquired 2,890 stock options on July 25, 2024, as part of an annual non-employee director award.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales of common stock on July 23 and 24, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on July 19 and July 22, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on July 17 and 18, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on July 15 and 16, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales under a pre-arranged 10b5-1 trading plan.

Director Christopher Patusky reports acquisition of 900 shares of United Therapeutics common stock upon vesting of restricted stock units.

Director Judy D. Olian reports the vesting of restricted stock units and subsequent conversion into common stock of United Therapeutics.

Director Nilda Mesa reports the vesting of restricted stock units and subsequent conversion into common stock of United Therapeutics.

Director Ray Kurzweil reports the vesting of restricted stock units into common stock of United Therapeutics.

Director Richard Giltner reports the vesting of restricted stock units and subsequent conversion into common stock of United Therapeutics.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on July 9th and 10th, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on July 5th and July 8th, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales under a pre-arranged 10b5-1 trading plan on July 2nd and 3rd, 2024.